Top

Diabetologia

Published in:

01-06-2007 | Article

Circulating leptin levels are not associated with cardiovascular morbidity and mortality in women with diabetes: a prospective cohort study

Authors: A. M. Brennan, T. Y. Li, I. Kelesidis, A. Gavrila, F. B. Hu, C. S. Mantzoros

Published in: Diabetologia | Issue 6/2007

Abstract

Aims/hypothesis

Leptin, an adipocyte-secreted hormone, plays an important role in regulating neuroendocrine and immune function as well as insulin resistance and metabolism. Our objective was to examine the relationship between leptin levels and cardiovascular morbidity and overall mortality in women with type 2 diabetes.

Subjects and methods

This prospective cohort study included 1,194 women with a confirmed diagnosis of type 2 diabetes, who provided a blood sample at baseline in 1989–1990. Participants were followed for 12 years for the development of health outcomes including cardiovascular disease (CVD) events as well as total mortality.

Results

There were 218 new CVD events and 228 deaths from all causes. Cox proportional hazards analysis was used to estimate the relative risks (RRs) for each quintile level of leptin compared with the lowest quintile. Leptin levels were positively associated with several CVD risk factors including BMI and inflammatory markers, but were not independently associated with the incidence of CVD or total mortality in women with diabetes. The multivariate RRs (95% CIs) for CVD across the quintiles of leptin were 0.96 (0.61–1.53), 0.99 (0.61–1.61), 1.04 (0.63–1.71), 1.02 (0.59–1.75) (p for trend = 0.83).

Conclusions/interpretation

Although circulating leptin levels are associated with obesity and inflammatory markers, they are not significantly related to the risk of CVD or mortality in women with diabetes.

Howard JK, Lord GM, Matarese G et al (1999) Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J Clin Invest 104:1051–1059PubMedCrossRef

Farooqi IS, Matarese G, Lord GM et al (2002) Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110:1093–1103PubMedCrossRef

Chan JL, Moschos SJ, Bullen J et al (2005) Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-alpha receptor levels in humans with relative leptin deficiency. J Clin Endocrinol Metab 90:1625–1631PubMedCrossRef

Welt CK, Chan JL, Bullen J et al (2004) Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 351:987–997PubMedCrossRef

Considine RV, Sinha MK, Heiman ML et al (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292–295PubMedCrossRef

Shamsuzzaman AS, Winnicki M, Wolk R et al (2004) Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 109:2181–2185PubMedCrossRef

van Dielen FM, van’t Veer C, Schols AM, Soeters PB, Buurman WA, Greve JW (2001) Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord 25:1759–1766PubMedCrossRef

Gomez-Ambrosi J, Salvador J, Paramo JA et al (2002) Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. Clin Biochem 35:315–320PubMedCrossRef

Gomez-Ambrosi J, Salvador J, Silva C et al (2005) Leptin therapy does not affect inflammatory markers. J Clin Endocrinol Metab 90:3803PubMedCrossRef

10.

Canavan B, Salem RO, Schurgin S et al (2005) Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. J Clin Endocrinol Metab 90:5779–5785PubMedCrossRef

11.

Chan JL, Bullen J, Stoyneva V, DePaoli AM, Addy C, Mantzoros CS (2005) Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess. J Clin Endocrinol Metab 90:1618–1624PubMedCrossRef

12.

Wallace AM, McMahon AD, Packard CJ et al (2001) Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 104:3052–3056PubMed

13.

Soderberg S, Ahren B, Jansson JH et al (1999) Leptin is associated with increased risk of myocardial infarction. J Intern Med 246:409–418PubMedCrossRef

14.

Soderberg S, Ahren B, Stegmayr B et al (1999) Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke 30:328–337PubMed

15.

Soderberg S, Stegmayr B, Stenlund H et al (2004) Leptin, but not adiponectin, predicts stroke in males. J Intern Med 256:128–136PubMedCrossRef

16.

Couillard C, Lamarche B, Mauriege P et al (1998) Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Diabetes Care 21:782–786PubMedCrossRef

17.

Piemonti L, Calori G, Mercalli A et al (2003) Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care 26:2883–2889PubMedCrossRef

18.

Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB (2005) Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 90:4542–4548PubMedCrossRef

19.

Manson JE, Colditz GA, Stampfer MJ et al (1991) A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 151:1141–1147PubMedCrossRef

20.

Shai I, Schulze MB, Manson JE, Stampfer MJ, Rifai N, Hu FB (2005) A prospective study of lipoprotein(a) and risk of coronary heart disease among women with type 2 diabetes. Diabetologia 48:1469–1476PubMedCrossRef

21.

Tanasescu M, Cho E, Manson JE, Hu FB (2004) Dietary fat and cholesterol and the risk of cardiovascular disease among women with type 2 diabetes. Am J Clin Nutr 79:999–1005PubMed

22.

Gavrila A, Chan JL, Yiannakouris N et al (2003) Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 88:4823–4831PubMedCrossRef

23.

Ma Z, Gingerich RL, Santiago JV, Klein S, Smith CH, Landt M (1996) Radioimmunoassay of leptin in human plasma. Clin Chem 42:942–946PubMed

24.

Hu FB, Meigs JB, Li TY, Rifai N, Manson JE (2004) Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53:693–700PubMedCrossRef

25.

Shai I, Rosner BA, Shahar DR et al (2005) Dietary evaluation and attenuation of relative risk: multiple comparisons between blood and urinary biomarkers, food frequency, and 24-hour recall questionnaires: the DEARR study. J Nutr 135:573–579PubMed

26.

Oral EA, Simha V, Ruiz E et al (2002) Leptin-replacement therapy for lipodystrophy. N Engl J Med 346:570–578PubMedCrossRef

27.

Javor ED, Cochran EK, Musso C, Young JR, DePaoli AM, Gorden P (2005) Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 54:1994–2002PubMedCrossRef

28.

Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS (2006) Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 91:2605–2611PubMedCrossRef

Title: Circulating leptin levels are not associated with cardiovascular morbidity and mortality in women with diabetes: a prospective cohort study
Authors: A. M. Brennan
T. Y. Li
I. Kelesidis
A. Gavrila
F. B. Hu
C. S. Mantzoros
Publication date: 01-06-2007
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 6/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-007-0635-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims/hypothesis

Subjects and methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 6/2007

Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study

Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis

Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions

Can we out-run the diabetes epidemic?

Relationship between increased relative birthweight and infections during pregnancy in children with a high-risk diabetes HLA genotype

Genetic association of single nucleotide polymorphisms in endonuclease G-like 1 gene with type 2 diabetes in a Japanese population

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials